Digital therapeutics world first for Big Health in ScotlandUK-based Big Health has passed a digital health milestone after Scotland became the first country to make anxiety Share XDigital therapeutics world first for Big Health in Scotlandhttps://pharmaphorum.com/news/digital-therapeutics-world-first-big-health-scotland/
Collaborate to simplify cancer trials and accelerate post-pandemic recoveryHow could simplifying the administration of clinical trials help cancer diagnosis, care, and treatment levels to exceed pre-pandemic Share XCollaborate to simplify cancer trials and accelerate post-pandemic recoveryhttps://pharmaphorum.com/views-and-analysis/collaborate-to-simplify-cancer-trials-and-accelerate-post-pandemic-recovery/
Scotland backs Bavencio for bladder cancer after NICE says noPatients with bladder cancer in Scotland will be the first in the UK to claim access to maintenance Share XScotland backs Bavencio for bladder cancer after NICE says nohttps://pharmaphorum.com/news/scotland-backs-bavencio-for-bladder-cancer-after-nice-says-no/
Scotland backs rare blood cancer drug Poteligeo rejected by NICEA north-south divide has emerged in UK medicines access after the Scottish Medicines Consortium (SMC) okayed Kyowa Kirin’s Share XScotland backs rare blood cancer drug Poteligeo rejected by NICEhttps://pharmaphorum.com/news/scotland-backs-rare-blood-cancer-drug-poteligeo-rejected-by-nice/
Scotland backs NHS use of Alexion’s Ultomiris for rare disease aHUSNHS patients in Scotland with the rare disease atypical haemolytic uremic syndrome (aHUS) will now be able to Share XScotland backs NHS use of Alexion’s Ultomiris for rare disease aHUShttps://pharmaphorum.com/news/scotland-backs-nhs-use-of-alexions-ultomiris-for-rare-disease-ahus/
Scotland opens door to Translarna for Duchenne muscular dystrophyA disparity in UK access to a medicine for Duchenne muscular dystrophy (DMD) has been addressed, after Scotland Share XScotland opens door to Translarna for Duchenne muscular dystrophyhttps://pharmaphorum.com/news/scotland-opens-door-to-translarna-for-duchenne-muscular-dystrophy/
Double first for Scotland as it backs Roche’s Rozlytrek, Novartis’ ZolgensmaThe Scottish Medicines Consortium (SMC) has said Roche’s Rozlytrek can be used by NHS Scotland for the treatment Share XDouble first for Scotland as it backs Roche’s Rozlytrek, Novartis’ Zolgensmahttps://pharmaphorum.com/news/double-first-for-scotland-as-it-backs-roches-rozlytrek-novartis-zolgensma/
How does HTA for orphan drugs differ across Europe?New research looks at the factors that speed up and slow down HTA appraisals for rare disease medicines Share XHow does HTA for orphan drugs differ across Europe?https://pharmaphorum.com/views-analysis-market-access/how-does-hta-for-orphan-drugs-differ-across-europe/
Scotland backs AZ’s Lynparza for first-line ovarian cancer maintenanceThe Scottish Medicines Consortium (SMC) has backed routine funding of AstraZeneca and MSD’s Lynparza as a maintenance treatment Share XScotland backs AZ’s Lynparza for first-line ovarian cancer maintenancehttps://pharmaphorum.com/news/scotland-backs-azs-lynparza-for-first-line-ovarian-cancer-maintenance/
